NZ621972A - Nanoparticle comprising rapamycin and albumin as anticancer agent - Google Patents

Nanoparticle comprising rapamycin and albumin as anticancer agent

Info

Publication number
NZ621972A
NZ621972A NZ621972A NZ62197208A NZ621972A NZ 621972 A NZ621972 A NZ 621972A NZ 621972 A NZ621972 A NZ 621972A NZ 62197208 A NZ62197208 A NZ 62197208A NZ 621972 A NZ621972 A NZ 621972A
Authority
NZ
New Zealand
Prior art keywords
inhibitor
agent
derivative
rapamycin
composition
Prior art date
Application number
NZ621972A
Other languages
English (en)
Inventor
Neil P Desai
Patrick Soon-Shiong
Vuong Trieu
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Priority to NZ711695A priority Critical patent/NZ711695A/en
Publication of NZ621972A publication Critical patent/NZ621972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ621972A 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent NZ621972A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ711695A NZ711695A (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US90573507P 2007-03-07 2007-03-07
US90573407P 2007-03-07 2007-03-07
US90576707P 2007-03-07 2007-03-07
US90566907P 2007-03-07 2007-03-07
US90567207P 2007-03-07 2007-03-07
US90566207P 2007-03-07 2007-03-07
US90578707P 2007-03-07 2007-03-07
US90575007P 2007-03-07 2007-03-07
US90566307P 2007-03-07 2007-03-07
US92324807P 2007-04-13 2007-04-13
US92345607P 2007-04-13 2007-04-13
NZ60006408 2008-03-07

Publications (1)

Publication Number Publication Date
NZ621972A true NZ621972A (en) 2015-09-25

Family

ID=39562000

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ621972A NZ621972A (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent
NZ711695A NZ711695A (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ711695A NZ711695A (en) 2007-03-07 2008-03-07 Nanoparticle comprising rapamycin and albumin as anticancer agent

Country Status (24)

Country Link
US (7) US8911786B2 (enExample)
EP (4) EP3417859A1 (enExample)
JP (6) JP2010520289A (enExample)
KR (5) KR101943230B1 (enExample)
CN (1) CN104814930B (enExample)
AU (1) AU2008223334B2 (enExample)
BR (1) BRPI0808635B1 (enExample)
CA (3) CA3201293A1 (enExample)
CY (3) CY1120555T1 (enExample)
DK (3) DK2131821T3 (enExample)
ES (3) ES2690175T3 (enExample)
HR (3) HRP20181159T1 (enExample)
HU (3) HUE038701T2 (enExample)
IL (2) IL200755A (enExample)
LT (3) LT2481402T (enExample)
MX (2) MX2009009537A (enExample)
NZ (2) NZ621972A (enExample)
PL (3) PL2131821T3 (enExample)
PT (3) PT2131821T (enExample)
RU (3) RU2483714C2 (enExample)
SI (3) SI2131821T1 (enExample)
UA (1) UA118645C2 (enExample)
WO (1) WO2008109163A1 (enExample)
ZA (1) ZA200906342B (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUE040046T2 (hu) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
TR200801337T1 (tr) * 2005-08-31 2008-07-21 Abraxis Bioscience, Llc. Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
PL2117520T3 (pl) 2006-12-14 2019-03-29 Abraxis Bioscience, Llc Terapia raka piersi w oparciu o status występowania receptora hormonalnego przy użyciu nanocząstek zawierających taksan
PT2131821T (pt) * 2007-03-07 2018-10-10 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20160116062A (ko) 2008-06-16 2016-10-06 바인드 쎄라퓨틱스, 인크. 약물 부하된 중합체성 나노입자, 및 이의 제조 및 사용 방법
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
PT2370076T (pt) * 2008-11-28 2017-03-31 Novartis Ag Combinações de inibidor hsp90
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2965763B8 (en) * 2009-04-10 2018-08-15 Haiyan Qi Anti-aging agents
CA2758913A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion free nanoparticle compositions and methods of making thereof
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
KR20190109593A (ko) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
KR20180049180A (ko) 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012054564A2 (en) * 2010-10-19 2012-04-26 The Curators Of The University Of Missouri Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
JP6038123B2 (ja) * 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
AU2012249540B2 (en) 2011-04-29 2017-07-13 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
US9731012B2 (en) * 2012-03-30 2017-08-15 President And Fellows Of Harvard College Laser-actuated therapeutic nanoparticles
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
JP2015526471A (ja) * 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
JP6356678B2 (ja) 2012-09-17 2018-07-11 ファイザー・インク 治療用ナノ粒子を製造する方法
CA2885022A1 (en) * 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
ES2899643T3 (es) 2012-10-01 2022-03-14 Mayo Found Medical Education & Res Tratamientos para el cáncer
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
EP2941301A4 (en) * 2013-01-03 2016-08-17 Univ Texas RAPAMYCIN ANALOGUE TREATED ON PROTEASOME FUNCTION IN THE TREATMENT OF CANCER
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
US9962373B2 (en) * 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
EP2967059A4 (en) * 2013-03-15 2017-03-22 The Board of Regents of The University of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
KR101329646B1 (ko) * 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
AU2014262164B2 (en) * 2013-05-03 2020-02-27 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
EP2991646B1 (en) 2013-05-03 2020-10-07 Selecta Biosciences, Inc. Methods and compositions for enhancing cd4+ regulatory t cells
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
SMT202000162T1 (it) 2013-09-16 2020-05-08 Astrazeneca Ab Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse
CN106061470A (zh) * 2013-10-22 2016-10-26 北卡罗来纳大学查珀尔希尔分校 含有多种物质的聚合物纳米粒子及其方法
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CA2942859A1 (en) 2014-03-14 2015-09-17 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
JP6695286B2 (ja) 2014-06-13 2020-05-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ リンパ腫の処置
WO2015195476A1 (en) 2014-06-16 2015-12-23 Mayo Foundation For Medical Education And Research Treating myelomas
EP3189147A1 (en) 2014-09-07 2017-07-12 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
WO2016172069A1 (en) * 2015-04-20 2016-10-27 Washington State University Methods of treating inflammation associated airway diseases and viral infections
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
CA2988593C (en) 2015-06-16 2023-10-24 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN116473964A (zh) * 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
CA2990703C (en) * 2015-06-29 2024-04-30 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
CA2990705A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
JP2018521058A (ja) * 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
AU2016308337B2 (en) * 2015-08-18 2019-02-28 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
US20220280233A1 (en) * 2015-12-23 2022-09-08 Theromics, Inc. Devices, methods, and compositions for thermal acceleration and drug delivery
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
JP7104627B2 (ja) * 2016-02-04 2022-07-21 ザ・ジョンズ・ホプキンス・ユニバーシティ ラパグルチン（ｒａｐａｇｌｕｔｉｎｓ）、ｇｌｕｔの新規阻害剤及びその使用
CA3013650A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research TREATMENTS FOR BLOOD CANCER
JP2019511903A (ja) 2016-02-19 2019-05-09 ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ 免疫原性調節の方法
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
KR20220151022A (ko) 2016-09-01 2022-11-11 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
JP2019526587A (ja) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｐｄ−ｌ１を発現する癌を処置する方法
RU2756892C2 (ru) 2016-09-06 2021-10-06 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
BR112019006113A2 (pt) * 2016-09-28 2019-06-18 Abraxis Bioscience Llc métodos de tratamento de distúrbios mitocondriais e metabólicos
WO2018128173A1 (en) * 2017-01-06 2018-07-12 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
WO2019073371A1 (en) 2017-10-11 2019-04-18 Wockhardt Limited PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES
US20190184031A1 (en) * 2017-12-19 2019-06-20 Abraxis Bioscience, Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
CA3086710A1 (en) * 2017-12-21 2019-06-27 The Angiogenesis Foundation Compositions and methods for treating neoplasia
EP3755303A1 (en) * 2018-02-23 2020-12-30 Biotronik AG Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures
MX2020009740A (es) * 2018-03-20 2021-01-20 Abraxis Bioscience Llc Metodos para el tratamiento de trastornos del sistema nervioso central mediante la administracion de nanoparticulas de un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y una albumina.
JP7561628B2 (ja) 2018-05-22 2024-10-04 アブラクシス バイオサイエンス， エルエルシー 肺高血圧症を処置するための方法および組成物
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CN113795287A (zh) * 2019-03-19 2021-12-14 阿布拉科斯生物科学有限公司 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
US20220257523A1 (en) * 2019-07-16 2022-08-18 The Regents Of The University Of Michigan Composite drug particles and uses thereof
AU2020375810A1 (en) * 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
BR112022009018A2 (pt) * 2019-11-11 2022-10-11 Abraxis Bioscience Llc Biomarcadores para composições de nanopartícula
KR102641217B1 (ko) * 2019-12-24 2024-02-29 (주)아이엠지티 항암제가 코팅된 알부민 나노입자 및 이의 제조방법
KR102517033B1 (ko) 2020-07-15 2023-04-03 성균관대학교산학협력단 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JP2023552809A (ja) * 2020-12-10 2023-12-19 チルドレンズ ホスピタル メディカル センター 増強されたナノ粒子送達システム
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
US20240226104A1 (en) * 2021-04-20 2024-07-11 The Regents Of The University Of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
KR102837034B1 (ko) 2022-09-28 2025-07-22 충남대학교산학협력단 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
CN116271067A (zh) * 2023-03-20 2023-06-23 山东大学齐鲁医院 一种基于hsp90抑制剂白蛋白纳米药物及其制备方法与应用
WO2024228964A1 (en) 2023-04-30 2024-11-07 Aadi Bioscience, Inc. Treatments comprising an mtor inhibitor nanoparticle composition
WO2024243413A1 (en) 2023-05-24 2024-11-28 Aadi Bioscience, Inc. Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma
WO2025034870A1 (en) 2023-08-08 2025-02-13 Aadi Bioscience, Inc. Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers
WO2025049962A1 (en) 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
WO2025129108A1 (en) 2023-12-14 2025-06-19 Aadi Bioscience, Inc. Methods of treating a cancer in an individual

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070117862A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1683517A1 (en) 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
CZ303611B6 (cs) * 2001-02-19 2013-01-09 Novartis Ag Farmaceutické prostredky s obsahem derivátu rapamycinu pro lécení solidních nádoru
NZ540047A (en) 2001-04-06 2007-01-26 Wyeth Corp Use of combination consisting of rapamycin 42-ester with CCI-779, 5-fluorouracil and/or gemcitabine and optionally leucovorin and/or levofolinate for treating a neoplasm
SG153647A1 (en) * 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4212921B2 (ja) * 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
WO2003086178A2 (en) 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
KR20140027554A (ko) * 2002-12-09 2014-03-06 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
HUE040046T2 (hu) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20050038498A1 (en) 2003-04-17 2005-02-17 Nanosys, Inc. Medical device applications of nanostructured surfaces
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP2784082B1 (en) * 2004-05-14 2017-12-27 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel.
US20080280939A1 (en) 2004-05-17 2008-11-13 Siego Izumo Combination of Organic Compounds
EP3173072A1 (en) * 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006053754A1 (en) 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
WO2006089207A2 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0607139A2 (pt) * 2005-02-18 2009-08-11 M S Abdou conjunto de fixação de osso
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2008533165A (ja) 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミティド ナノ粒子免疫抑制性化合物の注射可能組成物
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US7514549B2 (en) * 2005-04-16 2009-04-07 Michigan State University Tumor inhibition by modulating sprouty expression or activity
KR20080007607A (ko) 2005-05-16 2008-01-22 노파르티스 아게 심혈관 질환의 치료 및/또는 예방을 위한 라파마이신유도체의 용도
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
TR200801337T1 (tr) 2005-08-31 2008-07-21 Abraxis Bioscience, Llc. Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
US20070148251A1 (en) * 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
JP2010502603A (ja) 2006-08-31 2010-01-28 アブラクシス バイオサイエンス， エルエルシー 血管形成を阻害し、血管形成関連疾患を処置する方法
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
PL2117520T3 (pl) 2006-12-14 2019-03-29 Abraxis Bioscience, Llc Terapia raka piersi w oparciu o status występowania receptora hormonalnego przy użyciu nanocząstek zawierających taksan
PT2131821T (pt) 2007-03-07 2018-10-10 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
AU2009234127B2 (en) 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US20120128732A1 (en) 2008-12-11 2012-05-24 Vuong Trieu Combinations and modes of administration of therapeutic agents and combination therapy
KR101739598B1 (ko) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 티오콜키신 유도체와의 조합 요법
EP2416650B1 (en) 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
CA2758913A1 (en) 2009-04-15 2010-10-21 Abraxis Bioscience, Llc Prion free nanoparticle compositions and methods of making thereof
AU2010286670B2 (en) 2009-08-25 2016-04-21 Abraxis Bioscience, Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
KR20190109593A (ko) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
MX343671B (es) 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
KR20180049180A (ko) * 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9962373B2 (en) * 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer

Also Published As

Publication number Publication date
US20150050356A1 (en) 2015-02-19
LT2481402T (lt) 2018-10-25
EP2481402A2 (en) 2012-08-01
EP2481409A2 (en) 2012-08-01
KR20090118999A (ko) 2009-11-18
LT2481409T (lt) 2018-10-25
RU2483714C2 (ru) 2013-06-10
HRP20181198T1 (hr) 2018-10-05
PL2131821T3 (pl) 2018-11-30
US8911786B2 (en) 2014-12-16
EP2481409B1 (en) 2018-05-09
KR102154459B1 (ko) 2020-09-09
KR20190009842A (ko) 2019-01-29
EP3417859A1 (en) 2018-12-26
DK2481402T3 (en) 2018-08-06
CA3006137C (en) 2023-08-01
CA3201293A1 (en) 2008-09-12
JP6348698B2 (ja) 2018-06-27
PL2481409T3 (pl) 2018-11-30
EP2131821A1 (en) 2009-12-16
BRPI0808635A2 (pt) 2014-08-05
CY1120548T1 (el) 2019-07-10
MX2009009537A (es) 2009-09-16
HUE039643T2 (hu) 2019-01-28
EP2481402B1 (en) 2018-05-09
PT2131821T (pt) 2018-10-10
RU2013109422A (ru) 2014-09-10
US20240065984A1 (en) 2024-02-29
KR20150002886A (ko) 2015-01-07
JP2017132810A (ja) 2017-08-03
KR102047634B1 (ko) 2019-11-21
CN104814930B (zh) 2019-12-17
RU2678448C2 (ru) 2019-01-29
DK2481409T3 (en) 2018-08-06
US20210322335A1 (en) 2021-10-21
HUE039497T2 (hu) 2019-01-28
EP2131821B1 (en) 2018-05-09
ES2686150T3 (es) 2018-10-16
CA3006137A1 (en) 2008-09-12
CA2680207A1 (en) 2008-09-12
CA2680207C (en) 2018-07-03
ZA200906342B (en) 2010-11-24
LT2131821T (lt) 2018-09-25
HRP20181159T1 (hr) 2018-11-02
EP2481402A3 (en) 2012-10-17
NZ711695A (en) 2017-05-26
US20100183728A1 (en) 2010-07-22
KR101943230B1 (ko) 2019-01-28
ES2690175T3 (es) 2018-11-19
JP2014015487A (ja) 2014-01-30
BRPI0808635B1 (pt) 2022-06-07
CY1120555T1 (el) 2019-07-10
JP2018150381A (ja) 2018-09-27
KR20170014007A (ko) 2017-02-07
RU2009136992A (ru) 2011-04-20
US20250186359A1 (en) 2025-06-12
AU2008223334B2 (en) 2014-05-08
ES2690174T3 (es) 2018-11-19
IL200755A0 (en) 2010-05-17
HRP20181217T1 (hr) 2018-10-05
SI2481402T1 (sl) 2018-09-28
JP2020002177A (ja) 2020-01-09
CY1120547T1 (el) 2019-07-10
IL200755A (en) 2017-12-31
US20190022020A1 (en) 2019-01-24
JP2016011309A (ja) 2016-01-21
JP2010520289A (ja) 2010-06-10
PT2481409T (pt) 2018-10-18
JP6544812B2 (ja) 2019-07-17
MX380318B (es) 2025-03-12
EP2481409A3 (en) 2012-10-10
SI2481409T1 (sl) 2018-09-28
UA118645C2 (uk) 2019-02-25
PL2481402T3 (pl) 2018-11-30
RU2019101632A (ru) 2020-07-22
WO2008109163A1 (en) 2008-09-12
CN104814930A (zh) 2015-08-05
DK2131821T3 (en) 2018-08-06
KR20190130680A (ko) 2019-11-22
US20130280336A1 (en) 2013-10-24
AU2008223334A1 (en) 2008-09-12
PT2481402T (pt) 2018-10-18
HUE038701T2 (hu) 2018-11-28
IL250445A0 (en) 2017-03-30
SI2131821T1 (sl) 2018-11-30

Similar Documents

Publication Publication Date Title
NZ621972A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
BRPI0412798A (pt) uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação
IL185288A (en) An albumin-containing paclitaxel formulation in the form of nanoparticles for use in combination with other chemotherapeutic agents for cancer
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
JP2016519684A (ja) 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
IL201284A (en) K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment
JP2010520289A5 (enExample)
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
DE60203260D1 (de) Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2007059106A3 (en) Administration of mntor inhibitor to treat patients with cancer
JP2009515901A5 (enExample)
JP2005530735A5 (enExample)
WO2006026597A3 (en) Novel compositions and methods of treatment
WO2007067752A3 (en) Certain compositions and methods of treatment
UA97629C2 (ru) Фармацевтическая композиция, имеющая противоопухолевую активность, и способы
UY27670A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y de agentes inhibidores de la cinasa del egfr
Hanjani et al. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 07 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20160218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2022 BY CPA GLOBAL

Effective date: 20210129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2023 BY CPA GLOBAL

Effective date: 20220204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2024 BY CPA GLOBAL

Effective date: 20230202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250130